Chimeric antigen receptor (CAR) T-cell therapysolid tumorshematologic malignancies
…Background Chimeric antigen receptor (CAR) T-cell therapy has achieved clinical success in hematologic malignancies, but …
12articles mentioning treatments
12treatment mentions
1distinct treatments extracted
0%of mentions human-reviewed
Active filtersEntity: Chimeric Antigen Receptor (CAR) T-cell therapy ×
Chimeric Antigen Receptor (CAR) T-cell therapy
This treatment is selected. Its supporting articles are shown below.
Articles mentioning Chimeric Antigen Receptor (CAR) T-cell therapy
12 articles · page 1 of 1Chimeric antigen receptor (CAR) T-cell therapyleukemiahematological malignancieslymphoma
…Background Chimeric antigen receptor (CAR) T-cell therapy is a promising immunotherapy for patients with refractory or re…
chimeric antigen receptor (CAR) T-cell therapysecondary T-cell malignancyacademiagovernment
…Following administration of chimeric antigen receptor (CAR) T-cell therapy, extensive long-term follow-up (LTFU) requirements and complex …
Chimeric antigen receptor (CAR) T-cell therapydiffuse midline gliomas (DMGs)pediatric brain tumor
…Background Chimeric antigen receptor (CAR) T-cell therapy has demonstrated safety and modest efficacy against diffuse mid…
Chimeric antigen receptor (CAR) T-cell therapyB-cell malignanciesNCT05098613NCT05442515NCT06559189
…Background Chimeric antigen receptor (CAR) T-cell therapy is effective in treating B-cell malignancies, however relapse d…
86.8%
Chimeric antigen receptor (CAR) T-cell therapyUniversity of MarylandUniversity of Maryland Medical CenterAIC Kijabe Hospitalsolid tumorshematological malignanciesNational Commission for Science and TechnologyAKUHNAga Khan University HospitalMinistry of Health+1 more
…Background Chimeric antigen receptor (CAR) T-cell therapy has revolutionized cancer immunotherapy for hematological malig…
chimeric antigen receptor (CAR) T-cell therapyDiffuse Intrinsic Pontine GliomaDIPG
… brain tumor with median survival of less than 12 months. While chimeric antigen receptor (CAR) T-cell therapy shows promise, its efficacy in DIPG is limited by a profoundly …
79.1%
Chimeric antigen receptor (CAR) T-cell therapyGSK3685032pediatric brain tumorsmedulloblastomaZebularineAZAazacytidinehematologic malignanciespediatric gliomaU87
…Background Chimeric antigen receptor (CAR) T-cell therapy has transformed treatment for hematologic malignancies, but its…
Chimeric antigen receptor (CAR) T-cell therapysarcomamantle cell lymphomatumorClinicaltrials.gov
…Background Chimeric antigen receptor (CAR) T-cell therapy, effective in certain hematologic malignancies, still has the p…
chimeric antigen receptor (CAR) T-cell therapyOvarian cancerOVCARPMI + 10% FBS
…ded by the folate receptor 1 gene (FOLR1) provides a target for chimeric antigen receptor (CAR) T-cell therapy. To date the dynamicity and the spatiotemporal dynamics of CAR …
chimeric antigen receptor (CAR) T-cell therapyepithelial cancershematologic malignancies
…Background While chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of hematologic malignancies, i…
Chimeric Antigen Receptor (CAR) T-cell therapyheme malignanciessolid tumorsUniversity of PittsburghLohmueller Lab
…Background While Chimeric Antigen Receptor (CAR) T-cell therapy has revolutionized the treatment of heme malignancies, multiple…